Literature DB >> 34115033

Neutrophil-lymphocyte ratio as a prognostic factor for minute clear cell renal cell carcinoma diagnosed using multi-slice spiral CT.

Li Chen1, Lingjun Qi, Jing Zhang, Qian Ma, Xiaoxin Chai.   

Abstract

ABSTRACT: Minute clear cell renal cell carcinoma (MccRCC) has a diameter of <1.5 cm and can be diagnosed using multi-slice spiral CT (MSCT). Recently, the role of the neutrophil-lymphocyte ratio (NLR) in the development of MccRCC has attracted attention. This study aimed to further explore the relationship between the NLR and MccRCC.This was a prospective study of 100 patients who were diagnosed with MccRCC using MSCT at Urumqi Friendship Hospital, China. The study investigated a series of pretreatment factors, including NLR and patients' general clinical data. Statistical methods employed included Pearson's chi-square test, Spearman-rho correlation test, Cox regression analysis, and receiver operator characteristic curve analysis.Based on Pearson's χ2, Spearman-rho test, and univariate/multivariate Cox regression analysis, the overall survival of patients with MccRCC was shown to be significantly related to NLR (P < .001). NLR (hazard ratio = 50.676, 95%CI, 17.543-146.390, P < .001) is a significant independent risk-factor for MccRCC. A receiver operator characteristic curve was plotted to examine specificity and sensitivity between NLR and MccRCC (area under curve = 0.958, P < .001).The level of the NLR plays a crucial role in the survival of patients with MccRCC, as diagnosed with MSCT. The higher the NLR, the worse the prognosis for patients with MccRCC.
Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 34115033      PMCID: PMC8202639          DOI: 10.1097/MD.0000000000026292

Source DB:  PubMed          Journal:  Medicine (Baltimore)        ISSN: 0025-7974            Impact factor:   1.889


Introduction

Clear cell renal cell carcinoma originates from renal tubular epithelial cells, and its incidence is second only to bladder cancer among urinary tract carcinomas. It accounts for 85% to 90% of primary malignant renal tumors, with a mortality rate as high as 40%.[ Therefore, this is a highly malignant tumor of the urinary system.[ The etiology of clear cell renal cell carcinoma is unknown and may be related to obesity, smoking, long-term hemodialysis, or occupational factors. Clear cell renal cell carcinoma is the most common pathological type of renal carcinoma that is not sensitive to conventional radiotherapy or chemotherapy.[ As most patients with clear cell renal cell carcinoma have atypical clinical symptoms, currently the disease is mainly detected through the use of medical imaging examination. Almost 50% of renal cancers are discovered by chance, and about 25% of patients have metastases at the time of diagnosis.[ Small renal cell carcinoma (SRCC) refers to renal cell carcinomas with a diameter of <2.5 cm, while minute clear cell renal cell carcinoma (MccRCC) usually has a diameter of <1.5 cm.[ MccRCC has the characteristics of being clinically asymptomatic, with small lesions, and it is easy to miss during an investigation. It has been confirmed that tumor diameter is related to prognosis in renal cell carcinoma. In view of these characteristics of MccRCC, clinicians have found that early detection can be achieved through imaging examinations, such as multi-slice computed tomography (MSCT) and magnetic resonance imaging (MRI), leading to a better prognosis. MSCT is developed on the basis of single-layer spiral CT, which can obtain better three-dimensional (3D) reconstructed images, with larger scanning coverage, shorter scanning time, and higher z-axis resolution.[ It has been found that the application of multilayer helixes in clinical practice can greatly improve the detection rate and differential diagnosis of kidney tumors, especially microtumors,[ and is more conducive to the early diagnosis of the disease.[ MSCT can help to avoid small lesions being missed, which is beneficial to the detection and characterization of metastatic renal cell carcinoma. The neutrophil–lymphocyte ratio (NLR) is the ratio of the neutrophil to lymphocyte count.[ In recent years, a number of advances have been made in making use of the predictive value of the NLR. An increased NLR is strongly associated with disease severity and outcome. Pichler et al confirmed that increased NLR in patients with renal clear cell carcinoma is an independent risk factor for overall survival, which may reflect a higher risk of severe disease.[ NLR is an important inflammatory parameter. Inflammation is defined as 1 of the 10 characteristics associated with tumors. Tumer[ used HE staining to identify inflammatory cells that had infiltrated tumor tissue. Statistical analysis showed that the number of inflammatory cells infiltrating a tumor was positively correlated with overall survival and relapse-free survival of cancer patients, while the systemic inflammatory response was negatively correlated with the prognosis of cancer patients. Patients with low inflammatory cell infiltration and high peripheral blood NLR had a significantly worse prognosis than those with high inflammatory cell infiltration and low peripheral blood NLR. The combination of histological examination and routine blood data is more beneficial for determining cancer prognosis. Metastatic cancer is a reflection of advanced disease, and Nakayama et al[ considered that peripheral blood NLR can be used as an independent determinant of cancer metastasis. Cho et al[ found that peripheral blood NLR prior to treatment played a guiding role in the evaluation of chemotherapy efficacy and prognosis of survival time for metastatic advanced cancer. The Pearson chi-square, Spearman correlation analysis, univariate and multivariate Cox regression analysis, and receiver operating characteristic (ROC) curve were used in this study to explore and verify the relationship between NLR level and overall survival of patients with MccRCC. This may provide new directions for treatment and prediction of survival in patients with MccRCC.

Methods

Patients and groups

The study participants were 100 patients who were diagnosed with MccRCC using MSCT and who took part in a prospective study at Urumqi Friendship Hospital, China, between January 2012 and January 2020. The patients were divided into two groups according to overall survival based on their average survival time: short survival-time group (59 cases) and long survival-time group (41 cases). Patients’ clinical data were then analyzed to explore the role of NLR in MccRCC. The start point was when a participant was diagnosed with MccRCC by multi-slice spiral CT. The end point was when a participant died from MccRCC.

Ethics and patient consent

This study was approved by the Ethics Committee of the Urumqi Friendship Hospital. Written informed consent was obtained from all patients.

Inclusion and exclusion criteria

The inclusion criteria were 18 to 85 years old, diagnosed with MccRCC using MSCT, patients without surgical history, and good cooperation of patients and their families. Exclusion criteria included age <18 years or >85 years; patients with poor cardiac, pulmonary, liver, or kidney function; and patients requiring emergency surgery.

Collection of clinical indicators

Age, sex, neutrophil count, lymphocyte count, blood glucose, NLR, blood urea nitrogen, and serum creatinine of patients with MccRCC were carefully recorded. Furthermore, we divided each indicator into two groups based on the average value. For all patients, NLRs were determined upon diagnosis and prior to any treatment. Short survival time was defined when the patients’ survival time was ≤30 months, and long survival time was defined when the patients’ survival time was >30 months. A neutrophil count <4.05 × 109 was defined as low, and a neutrophil count >4.05 × 109 was defined as high. A lymphocyte count <2.10 × 109 was defined as low, and a lymphocyte count >2.10 × 109 was defined as high. Blood glucose <5 mmol/L was defined as low, and blood glucose >5 mmol/L was defined as high. NLR <1.16 was defined as low, and NLR >1.16 was defined as high. Blood urea nitrogen <5.11 mmol/L was defined as low, and blood urea nitrogen >5.11 mmol/L was defined as high. Serum creatinine <75 μmol/L was defined as low, and serum creatinine >75 μmol/L was defined as high.

Statistics

The data were expressed as numbers and percentages. Associations between the clinical parameters and survival time of patients with MccRCC were analyzed using Pearson's chi-squared test. The Spearman-rho test was executed to compare clinical data and overall survival (OS) for the correlation analysis. Univariate and multivariate Cox regression analysis was used to calculate the hazard ratio (HR) of survival time for potentially correlated factors. We also used the Kaplan–Meier method to explore OS. The area under the curve (AUC) of the NLR was compared using a ROC curve to analyze the relationship between NLR and MccRCC. All statistical analyses were conducted using SPSS software, version 21.0 (IBM Corp, Armonk, NY). A P-value <0.05 was considered statistically significant.

Results

Associations between patient characteristics and OS of MccRCC based on the χ2 test

Table 1 summarizes the possible relationship between a patient's clinical factors and overall survival, according to Pearson's chi-square test. Among individuals, the NLR was significantly correlated with overall survival (P < .001). However, there were no significant correlations between survival time and sex (P = .694), age (P = .508), neutrophil count (P = .280), lymphocyte count (P = .147), blood glucose (P = .091), blood urea nitrogen (P = .345), or serum creatinine (P = .494) in patients with MccRCC (Table 1).
Table 1

Relevant characteristics of patients with MccRCC and overall survival.

Overall survival
ParametersShort (%)Long (%)P
Sex.694
 Male5634 (34.0%)22 (22.0%)
 Female4425 (25.0%)19 (19.0%)
Age
 ≤653824 (24.0%)14 (14.0%).508
 >656235 (35.0%)27 (27.0%)
Neutrophil count
 Low4328 (28.0%)15 (15.0%).280
 High5731 (31.0%)26 (26.0%)
Lymphocyte count
 Low5536 (36.0%)19 (19.0%).147
 High4523 (23.0%)22 (22.0%)
Blood glucose
 Low5436 (36.0%)18 (18.0%).091
 High4623 (23.0%)23 (23.0%)
NLR
 Low465 (5.0%)41 (41.0%)<.001
 High5454 (54.0%)0 (0.0%)
Blood urea nitrogen
 Low5233 (33.0%)19 (19.0%).345
 High4826 (26.0%)22 (22.0%)
Serum creatinine
 Low4830 (30.0%)18 (18.0%).494
 High5229 (29.0%)23 (23.0%)

Pearson's chi-squared test was used.

P < .05.

Relevant characteristics of patients with MccRCC and overall survival. Pearson's chi-squared test was used. P < .05.

Further associations between patients’ characteristics and OS in MccRCC cases using Spearman's correlation test

To determine whether underlying correlational factors in patients with MccRCC have a significant impact on OS, a further correlation analysis was performed. Spearman's correlation coefficient showed a significant correlation between OS and NLR (ρ = −0.903, P < .001). However, there were no further associations between survival time of patients with MccRCC and sex (ρ = −0.039, P = .698), age (ρ = 0.066, P = .513), neutrophil count (ρ = 0.108, P = .285), lymphocyte count (ρ = 0.145, P = .150), blood glucose (ρ = −0.169, P = .093), blood urea nitrogen (ρ = 0.094, P = .350), or serum creatinine (ρ = 0.068, P = .499) (Table 2).
Table 2

The relationship between characteristics of patients and overall survival.

Overall survival
CharacteristicsρP
Sex0.039.698
Age0.066.513
Neutrophil count0.108.285
Lymphocyte count0.145.150
Blood glucose0.169.093
NLR–0.903<.001
Blood urea nitrogen0.094.350
Serum creatinine0.068.499

Spearman correlation test was used.

P < .05.

The relationship between characteristics of patients and overall survival. Spearman correlation test was used. P < .05.

Univariate Cox regression analysis for the proportional hazards analysis of correlative factors related to OS in patients with MccRCC

Table 3 describes the HRs and 95% confidence intervals (95% CI) between clinically relevant factors and overall survival time in patients with MccRCC. For the factor of NLR, OS in the high-level NLR group was significantly lower than in the low-level NLR group, and the HR was 32.467 (95%CI, 12.260–85.979, P < .001). However, there were no significant differences in OS in cases of MccRCC related to any of the following factors: sex (HR = 0.725, 95%CI, 0.048–1.123, P = .150), age (HR = 0.833, 95%CI, 0.537–0.292, P = .414), neutrophil count (HR = 0.949, 95%CI, 0.620–1.453, P = .811), lymphocyte count (HR = 0.879, 95%CI, 0.575–1.342, P = .549), blood glucose (HR = 0.642, 95% CI, 0.411–1.002, P = .051), blood urea nitrogen (HR = 0.919, 95%CI, 0.598–1.413, P = .702), and serum creatinine (HR = 0.768, 95%CI, 0.501–1.175, P = .223) (Fig. 1, Table 3).
Table 3

Characteristics and their effect on OS based on univariate Cox proportional regression analysis.

OS
CharacteristicsHR95% CIP
Sex1.150
 Male56
 Female440.7250.048–1.123
Age
 <65 years381.414
 ≥65 years620.8330.537–0.292
Neutrophil count
 Low431.811
 High570.9490.620–1.453
Lymphocyte count
 Low551.549
 High450.8790.575–1.342
Blood glucose
 Low541.051
 High460.6420.411–1.002
NLR
 Low461<.001
 High5432.46712.260–85.979
Blood urea nitrogen
 Low521.702
 High480.9190.598–1.413
Serum creatinine
 Low481.223
 High520.7680.501–1.175

95% CI = 95% confidence interval; HR = hazard ratio; OS = overall survival.

P < .05.

Figure 1

A comparison of various clinical parameters and their effect on overall survival in patients with MccRCC.

Characteristics and their effect on OS based on univariate Cox proportional regression analysis. 95% CI = 95% confidence interval; HR = hazard ratio; OS = overall survival. P < .05. A comparison of various clinical parameters and their effect on overall survival in patients with MccRCC.

Analysis of OS based on multivariate Cox regression analysis for the proportional hazards of related characteristics

To effectively control the influence of confounding factors, all factors were simultaneously incorporated into the multivariate Cox regression model. Table 4 shows the results of the multivariate Cox proportional regression analysis. NLR (HR = 50.676, 95% CI, 17.543–146.390, P < .001) and neutrophil count (HR = 1.874, 95% CI, 1.146–3.063, P = .012) were significantly associated with OS, whereas sex (HR = 0.668, 95%CI, 0.416–1.070, P = .093), age (HR = 0.847, 95%CI, 0.531–1.351, P = .485), lymphocyte count (HR = 1.399, 95%CI, 0.886–2.207, P = .149), blood glucose (HR = 0.982, 95%CI, 0.592–1.629, P = .945), blood urea nitrogen (HR = 1.359, 95%CI, 0.531–1.351, P = .485), and serum creatinine (HR = 0.914, 95%CI, 0.586–1.426, P = .692) showed no significant correlation with OS (Table 4).
Table 4

Characteristics and their effect on OS based on multivariate Cox regression analysis.

OS
CharacteristicsHR95% CIP
Sex0.6680.416–1.070.093
Age0.8470.531–1.351.485
Neutrophil count1.8741.146–3.063.012
Lymphocyte count1.3990.886–2.207.149
Blood glucose0.9820.592–1.629.945
NLR50.67617.543–146.390<.001
Blood urea nitrogen1.3590.834–2.215.218
Serum creatinine0.9140.586–1.426.692

95% CI = 95% confidence interval; HR = hazard ratio; OS = overall survival.

P < .05.

Characteristics and their effect on OS based on multivariate Cox regression analysis. 95% CI = 95% confidence interval; HR = hazard ratio; OS = overall survival. P < .05.

The ROC curve was used to analyze related factors in patients with MccRCC

The ROC curve analysis showed that the AUC of the NLR for predicting OS of patients with MccRCC was 0.958 (95%CI, 0.915–1.000, P < .001) (Fig. 2). However, sex (AUC = 0.520, 95%CI, 0.404–0.635, P = .737), age (AUC = 0.533, 95%CI, 0.418–0.648, P = .580), neutrophil count (AUC = 0.554, 95%CI, 0.440–0.669, P = .357), lymphocyte count (AUC = 0.573, 95%CI, 0.459–0.688, P = .214), blood glucose (AUC = 0.586, 95%CI, 0.471–0.700, P = .147), blood urea nitrogen (AUC = 0.548, 95%CI, 0.433–0.663, P = .416), and serum creatinine (AUC = 0.535, 95%CI, 0.419–0.650, P = .556) were not good predictors of OS in patients with MccRCC (Table 5).
Figure 2

The ROC curve of NLR for cases of MccRCC.

Table 5

Receiver operator characteristic curve analysis of N/L for MccRCC.

MccRCC
CharacteristicsAUCP95%CI
Sex0.520.7370.404–0.635
Age0.533.5800.418–0.648
Neutrophil count0.554.3570.440–0.669
Lymphocyte count0.573.2140.459–0.688
Blood glucose0.586.1470.471–0.700
NLR0.958 max<.0010.915–1.000
Blood urea nitrogen0.548.4160.433–0.663
Serum creatinine0.535.5560.419–0.650

AUC = area under curve; max = the maximum of AUC; NLR = neutrophil–lymphocyte ratio; MccRCC = minute clear cell renal cell carcinoma.

P ≤ .05.

The ROC curve of NLR for cases of MccRCC. Receiver operator characteristic curve analysis of N/L for MccRCC. AUC = area under curve; max = the maximum of AUC; NLR = neutrophil–lymphocyte ratio; MccRCC = minute clear cell renal cell carcinoma. P ≤ .05.

Analysis of metastasis-free survival and cancer-specific survival

Metastasis-free survival in the high-level NLR group was significantly lower than metastasis-free survival in the low-level NLR group; the HR was 21.51 (95%CI, 11.50–40.22, P < .001). Furthermore, cancer-specific survival in the high-level NLR group was significantly lower than in the low-level NLR group; the HR was 26.56 (95%CI, 13.99–50.39, P < .001) (Fig. 3).
Figure 3

Analysis of metastasis-free survival and cancer-specific survival. (A) Role of the NLR for the metastasis-free survival. (B) Role of the NLR for cancer-specific survival.

Analysis of metastasis-free survival and cancer-specific survival. (A) Role of the NLR for the metastasis-free survival. (B) Role of the NLR for cancer-specific survival.

Discussion

In this study, Pearson's chi-square test, Spearman correlation analysis, univariate and multivariate Cox regression analysis, and ROC curve analysis were used and determined that NLR is closely related to MccRCC outcomes. The higher their NLR, the worse the prognosis for patients with MccRCC. Kidney cancer, which accounts for 2% to 3% of all cancers and is on the rise, is a highly malignant tumor of the urinary system.[ In recent years, the widespread use of multi-slice CT (MSCT) and other radiographic imaging techniques has led to a significant increase in the percentage of small renal tumors that are accidentally detected during the asymptomatic stage. MccRCC has the characteristics of being clinically asymptomatic, with small lesions that are easy to miss, but MSCT offers a means to avoid missing small lesions and improve the detection and diagnosis of renal microtumors; therefore, it is widely recommended for the diagnosis of MccRCC.[ In contrast, laboratory tests, including C-reactive protein (CRP), urea nitrogen, creatinine, liver function, complete blood count (CBC), hemoglobin, blood glucose, alkaline phosphatase, and lactate dehydrogenase, play an important role in the diagnosis of minimal renal carcinoma. Among these, CRP, which is a serum marker of systemic inflammation, showed promise as a prognostic tool in patients with renal cell carcinoma.[ Pilskog et al confirmed that baseline CRP may be a useful biomarker in mRCC treatment plans.[ Kalogirou et al demonstrated the effectiveness of determining preoperative CRP level as a prognostic marker of survival in a cohort of patients with mRCC undergoing cell-reducing nephrectomy (CN).[ The NLR is a simple, cost-effective and readily available biomarker, which is commonly seen in various malignant tumors, inflammatory states, and inflammatory diseases.[ An increase in NLR is the result of both increased circulating neutrophils and decreased lymphocytes that cause systemic inflammation. NLR has been reported to be closely related to serum CRP levels. Meanwhile, NLR has also shown efficacy as an alternative marker for systemic inflammation in critically ill patients, malignancies, and chronic diseases such as end-stage kidney disease and diabetes.[ Eochagain et al demonstrated that inflammation and immunosuppression are involved in the pathogenesis of cancer and that an increased NLR reflects these processes and is associated with adverse outcomes of cancer.[ Selahattin et al found that NLR can be used as an indicator for preoperative diagnosis of renal cell carcinoma.[ Studies by Palin et al have found that NLR is significantly associated with increased colorectal cancer mortality. NLR is an inexpensive, simple, and effective clinical tool for predicting the prognosis of colorectal cancer patients.[ Mellor et al have shown that NLR is an important prognostic indicator of OS and DFS after R0 resection for gastric cancer, but its critical value remains unclear.[ Pichler[ found that in a large, validated European study of NLR pretreatment prognosis in 678 patients with renal cell carcinoma that preoperative NLR elevation was associated with poor OS, but not with cancer-specific outcomes. Ersan's[ research showed that there was a linear correlation between NLR and tumor size in renal cell carcinoma. Therefore, NLR is a cheap to measure biomarker that could be used to predict tumor size, and thus it may be used to gain insights into the prognosis of patients with RCC. Vincenzo's[ study concluded that higher NLR resulted in worse OS and progression-free survival (PFS) in the overall population (OS pooled HR 1.80; 95%CI: 1.61–2.00; I2 45%; PFS pooled HR of 1.69; 95%CI: 1.42–2.01; I2 81%). In addition, NLR is an easily accessible biomarker that can be used determine a prognosis in renal cell carcinoma. Selahattin[ found that the NLR may be a useful diagnostic biomarker parameter for renal cell carcinoma in the preoperative period. The findings of this earlier research are in agreement with those of our study. What was innovative about our study was that we targeted MccRCC diagnosed using multi-slice spiral CT; there has been little similar research into MccRCC. There were some limitations to our study. First, due to the limited number of patients in our hospital, elderly people (aged >85 years) were not included in this study. Second, this research was a single-center study, with no additional centers included for a large-scale investigation. In the future, we would make efforts to address these aspects.

Conclusion

This study confirmed that the NLR plays a crucial role in the prognosis of patients with MccRCC. The higher the NLR level, the lower the survival time of patients with MccRCC. This finding may provide a new perspective for the treatment and prognosis of patients with MccRCC.

Author contributions

Conceptualization: Lingjun Qi. Data curation: Xiaoxin Chai. Formal analysis: Li Chen. Funding acquisition: Lingjun Qi. Investigation: Qian Ma. Methodology: Li Chen, Lingjun Qi. Project administration: Qian Ma, Xiaoxin Chai. Resources: Jing Zhang. Software: Jing Zhang. Supervision: Xiaoxin Chai. Validation: Jing Zhang. Visualization: Qian Ma. Writing – original draft: Li Chen. Writing – review & editing: Xiaoxin Chai.
  30 in total

1.  Technique to retrieve implant abutment fragments.

Authors:  Ji-Hye Lee; Jong-Hyun Park; Chan-Jin Park; Lee-Ra Cho
Journal:  J Prosthet Dent       Date:  2015-06-20       Impact factor: 3.426

2.  Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.

Authors:  Robert J Motzer; Thomas E Hutson; Hilary Glen; M Dror Michaelson; Ana Molina; Timothy Eisen; Jacek Jassem; Jakub Zolnierek; Jose Pablo Maroto; Begoña Mellado; Bohuslav Melichar; Jiri Tomasek; Alton Kremer; Han-Joo Kim; Karen Wood; Corina Dutcus; James Larkin
Journal:  Lancet Oncol       Date:  2015-10-22       Impact factor: 41.316

3.  Usefulness of the neutrophil/lymphocyte ratio measured preoperatively as a predictor of peritoneal metastasis in patients with advanced gastric cancer.

Authors:  Yusuke Nakayama; Naoto Gotohda; Hidehito Shibasaki; Shogo Nomura; Takahiro Kinoshita; Ryuichi Hayashi
Journal:  Surg Today       Date:  2014-05-16       Impact factor: 2.549

Review 4.  Multi-slice CT (MSCT) imaging in pretrans-catheter aortic valve implantation (TAVI) screening. How to perform and how to interpret.

Authors:  George Latsios; Themistoklis N Spyridopoulos; Konstantinos Toutouzas; Andreas Synetos; George Trantalis; Konstantinos Stathogiannis; Vassiliki Penesopoulou; George Oikonomou; Elias Brountzos; Dimitrios Tousoulis
Journal:  Hellenic J Cardiol       Date:  2017-10-28

Review 5.  CT and MRI of small renal masses.

Authors:  Zhen J Wang; Antonio C Westphalen; Ronald J Zagoria
Journal:  Br J Radiol       Date:  2018-05-10       Impact factor: 3.039

6.  [Ultrasound-guided percutaneous radiofrequency ablation treatment for renal clear cell carcinoma].

Authors:  Xiangming Cheng; Weidong Gan; Linfeng Xu; Linfang Yao; Feng Qu; Gutian Zhang; Xiaogong Li; Hongqian Guo
Journal:  Zhonghua Wai Ke Za Zhi       Date:  2014-11

7.  Clear Cell Renal Cell Carcinoma: Associations Between CT Features and Patient Survival.

Authors:  Andreas M Hötker; Christoph A Karlo; Junting Zheng; Chaya S Moskowitz; Paul Russo; Hedvig Hricak; Oguz Akin
Journal:  AJR Am J Roentgenol       Date:  2016-03-02       Impact factor: 3.959

8.  The effect of anaesthetic technique during primary breast cancer surgery on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and return to intended oncological therapy.

Authors:  A Ní Eochagáin; D Burns; B Riedel; D I Sessler; D J Buggy
Journal:  Anaesthesia       Date:  2018-02-19       Impact factor: 6.955

9.  Neutrophil-to-Lymphocyte Ratio in Renal Cell Carcinoma Patients.

Authors:  Selahattin Çalışkan; Mustafa Sungur; Selçuk Kaba; Emrah Özsoy; Orhan Koca; Metin İshak Öztürk
Journal:  Folia Med (Plovdiv)       Date:  2018-11-29

10.  Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma.

Authors:  Martin Pilskog; Christian Beisland; Lars A Akslen; Leif Bostad; Åse Haug; Daniel Heinrich; Karin M Hjelle; Oddbjørn Straume
Journal:  BMC Urol       Date:  2017-08-31       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.